| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Opioid | 11 | 2024 | 40 | 3.210 |
Why?
|
| Nicotine | 14 | 2025 | 302 | 3.120 |
Why?
|
| Cocaine | 11 | 2024 | 251 | 2.800 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 5 | 2020 | 17 | 2.770 |
Why?
|
| Reward | 7 | 2025 | 112 | 2.430 |
Why?
|
| Conditioning, Operant | 7 | 2017 | 90 | 2.260 |
Why?
|
| Opioid Peptides | 11 | 2024 | 26 | 2.180 |
Why?
|
| beta-Endorphin | 6 | 2025 | 17 | 2.130 |
Why?
|
| Receptors, Opioid, mu | 5 | 2025 | 52 | 2.080 |
Why?
|
| Enkephalins | 5 | 2025 | 31 | 1.750 |
Why?
|
| Mice, Inbred C57BL | 26 | 2025 | 1869 | 1.510 |
Why?
|
| Mice, Knockout | 21 | 2025 | 1035 | 1.500 |
Why?
|
| Eating | 3 | 2025 | 167 | 1.420 |
Why?
|
| Motor Activity | 8 | 2013 | 437 | 1.410 |
Why?
|
| Mice | 39 | 2025 | 6644 | 1.380 |
Why?
|
| Animals | 53 | 2025 | 16992 | 1.160 |
Why?
|
| Morphine | 8 | 2013 | 69 | 1.080 |
Why?
|
| Nicotinic Agonists | 4 | 2019 | 88 | 1.040 |
Why?
|
| Cocaine-Related Disorders | 3 | 2015 | 102 | 1.010 |
Why?
|
| Cotinine | 3 | 2024 | 44 | 1.000 |
Why?
|
| Behavior, Animal | 5 | 2019 | 373 | 0.970 |
Why?
|
| Bulimia | 1 | 2025 | 4 | 0.950 |
Why?
|
| Analgesics, Opioid | 6 | 2013 | 252 | 0.880 |
Why?
|
| Food | 1 | 2025 | 103 | 0.860 |
Why?
|
| Feeding Behavior | 3 | 2025 | 469 | 0.850 |
Why?
|
| Dopamine Uptake Inhibitors | 5 | 2010 | 83 | 0.820 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2024 | 51 | 0.820 |
Why?
|
| Ethanol | 3 | 2018 | 224 | 0.740 |
Why?
|
| Male | 42 | 2025 | 23409 | 0.710 |
Why?
|
| Piperidines | 4 | 2018 | 83 | 0.690 |
Why?
|
| Pituitary Gland | 3 | 2020 | 60 | 0.690 |
Why?
|
| Motivation | 2 | 2020 | 513 | 0.680 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2020 | 1 | 0.650 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2020 | 126 | 0.610 |
Why?
|
| Spatial Behavior | 2 | 2012 | 22 | 0.610 |
Why?
|
| Locomotion | 3 | 2006 | 105 | 0.600 |
Why?
|
| Narcotics | 3 | 2013 | 29 | 0.580 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 77 | 0.580 |
Why?
|
| Indoles | 2 | 2018 | 187 | 0.570 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2017 | 1124 | 0.570 |
Why?
|
| Protein Precursors | 3 | 2013 | 59 | 0.540 |
Why?
|
| Homeostasis | 3 | 2017 | 192 | 0.530 |
Why?
|
| Carbohydrate Dehydrogenases | 5 | 2019 | 12 | 0.500 |
Why?
|
| Corticosterone | 5 | 2019 | 90 | 0.500 |
Why?
|
| Narcotic Antagonists | 8 | 2013 | 78 | 0.490 |
Why?
|
| Central Nervous System Depressants | 2 | 2018 | 42 | 0.480 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 74 | 0.460 |
Why?
|
| Cyclic AMP | 1 | 2015 | 127 | 0.450 |
Why?
|
| Buprenorphine | 2 | 2007 | 51 | 0.440 |
Why?
|
| Dynorphins | 2 | 2011 | 17 | 0.440 |
Why?
|
| Mental Disorders | 1 | 2019 | 392 | 0.440 |
Why?
|
| Analysis of Variance | 6 | 2019 | 575 | 0.400 |
Why?
|
| Dextroamphetamine | 1 | 2013 | 9 | 0.400 |
Why?
|
| Microsomes, Liver | 2 | 2024 | 75 | 0.390 |
Why?
|
| Opioid-Related Disorders | 2 | 2015 | 195 | 0.390 |
Why?
|
| Morphine Derivatives | 1 | 2012 | 3 | 0.370 |
Why?
|
| Stress, Psychological | 2 | 2010 | 661 | 0.370 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 2 | 0.370 |
Why?
|
| Smoking | 4 | 2022 | 1024 | 0.370 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 830 | 0.370 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2012 | 26 | 0.360 |
Why?
|
| Glucocorticoids | 3 | 2019 | 91 | 0.360 |
Why?
|
| Adipose Tissue | 3 | 2019 | 182 | 0.360 |
Why?
|
| Drug Tolerance | 4 | 2006 | 26 | 0.350 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 6 | 2019 | 16 | 0.340 |
Why?
|
| Analgesia | 1 | 2010 | 11 | 0.340 |
Why?
|
| Kidney | 2 | 2025 | 372 | 0.330 |
Why?
|
| Choice Behavior | 2 | 2013 | 93 | 0.320 |
Why?
|
| Blood Pressure | 2 | 2025 | 666 | 0.310 |
Why?
|
| Conditioning, Classical | 1 | 2010 | 67 | 0.310 |
Why?
|
| Female | 12 | 2024 | 24698 | 0.310 |
Why?
|
| Rats | 9 | 2024 | 3735 | 0.290 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2025 | 15 | 0.270 |
Why?
|
| Humans | 17 | 2024 | 43102 | 0.270 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 20 | 0.270 |
Why?
|
| Nociceptors | 2 | 2010 | 30 | 0.270 |
Why?
|
| Pain Measurement | 2 | 2010 | 183 | 0.270 |
Why?
|
| Pro-Opiomelanocortin | 3 | 2013 | 15 | 0.250 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 41 | 0.250 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 55 | 0.250 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 2 | 2025 | 6 | 0.230 |
Why?
|
| Insulin Resistance | 5 | 2019 | 201 | 0.230 |
Why?
|
| Time Factors | 5 | 2013 | 1857 | 0.220 |
Why?
|
| Appetite Regulation | 2 | 2017 | 9 | 0.220 |
Why?
|
| Lipolysis | 2 | 2014 | 20 | 0.220 |
Why?
|
| Brain | 2 | 2013 | 1472 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2017 | 1766 | 0.210 |
Why?
|
| Naltrexone | 3 | 2013 | 34 | 0.210 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 100 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 760 | 0.190 |
Why?
|
| Sex Factors | 2 | 2020 | 1028 | 0.190 |
Why?
|
| Taste Buds | 1 | 2022 | 3 | 0.190 |
Why?
|
| Ageusia | 1 | 2022 | 2 | 0.190 |
Why?
|
| Melatonin | 1 | 2023 | 82 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2008 | 35 | 0.190 |
Why?
|
| Adiposity | 3 | 2019 | 157 | 0.180 |
Why?
|
| Naloxone | 2 | 2013 | 56 | 0.180 |
Why?
|
| Anxiety | 2 | 2020 | 874 | 0.180 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 153 | 0.180 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 81 | 0.180 |
Why?
|
| Genotype | 2 | 2019 | 800 | 0.180 |
Why?
|
| Drug Interactions | 3 | 2012 | 150 | 0.180 |
Why?
|
| Tobacco Use Disorder | 2 | 2020 | 250 | 0.180 |
Why?
|
| Oxides | 1 | 2022 | 100 | 0.180 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 532 | 0.170 |
Why?
|
| Benzimidazoles | 3 | 2007 | 43 | 0.160 |
Why?
|
| Mecamylamine | 1 | 2020 | 21 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 241 | 0.160 |
Why?
|
| Aerosols | 1 | 2019 | 54 | 0.150 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 53 | 0.150 |
Why?
|
| Energy Metabolism | 2 | 2017 | 187 | 0.150 |
Why?
|
| Association Learning | 2 | 2010 | 35 | 0.150 |
Why?
|
| Neurons | 4 | 2017 | 1263 | 0.150 |
Why?
|
| Self Administration | 1 | 2019 | 69 | 0.150 |
Why?
|
| Schizophrenia | 1 | 2019 | 93 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.140 |
Why?
|
| Hypertension | 1 | 2025 | 835 | 0.140 |
Why?
|
| Obesity, Abdominal | 1 | 2018 | 29 | 0.140 |
Why?
|
| Cricetulus | 1 | 2018 | 82 | 0.140 |
Why?
|
| CHO Cells | 1 | 2018 | 123 | 0.140 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2017 | 8 | 0.140 |
Why?
|
| Abdominal Fat | 2 | 2014 | 21 | 0.130 |
Why?
|
| Benzamides | 1 | 2018 | 81 | 0.130 |
Why?
|
| Hepatocytes | 3 | 2008 | 80 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2018 | 77 | 0.130 |
Why?
|
| Obesity | 3 | 2023 | 1151 | 0.130 |
Why?
|
| Depression | 2 | 2023 | 863 | 0.130 |
Why?
|
| Water | 1 | 2019 | 316 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2013 | 52 | 0.120 |
Why?
|
| Hot Temperature | 2 | 2010 | 141 | 0.120 |
Why?
|
| Injections, Intraventricular | 2 | 2009 | 59 | 0.120 |
Why?
|
| Extinction, Psychological | 1 | 2017 | 104 | 0.120 |
Why?
|
| Proprotein Convertase 1 | 2 | 2013 | 10 | 0.120 |
Why?
|
| Proprotein Convertase 2 | 2 | 2013 | 19 | 0.120 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 300 | 0.120 |
Why?
|
| Astrocytes | 1 | 2017 | 244 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 47 | 0.110 |
Why?
|
| Embryonic Stem Cells | 1 | 2015 | 55 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2017 | 258 | 0.110 |
Why?
|
| Neurogenesis | 1 | 2015 | 63 | 0.110 |
Why?
|
| Liver | 3 | 2013 | 511 | 0.110 |
Why?
|
| Adipose Tissue, White | 1 | 2014 | 18 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2014 | 124 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1596 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1019 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2014 | 171 | 0.100 |
Why?
|
| Endocrine System Diseases | 2 | 2012 | 16 | 0.100 |
Why?
|
| Morphine Dependence | 1 | 2013 | 23 | 0.100 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2013 | 14 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2017 | 1621 | 0.100 |
Why?
|
| Antiporters | 1 | 2013 | 14 | 0.100 |
Why?
|
| Gene Expression Regulation | 5 | 2013 | 1070 | 0.100 |
Why?
|
| Injections, Subcutaneous | 2 | 2013 | 36 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 436 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 665 | 0.090 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 13 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 2012 | 31 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1003 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 783 | 0.090 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 48 | 0.090 |
Why?
|
| Pyrroles | 1 | 2012 | 72 | 0.090 |
Why?
|
| Adipocytes | 3 | 2018 | 60 | 0.090 |
Why?
|
| Body Composition | 1 | 2011 | 159 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 139 | 0.080 |
Why?
|
| Swimming | 1 | 2010 | 41 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2021 | 299 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 2 | 2008 | 60 | 0.080 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2010 | 80 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 113 | 0.080 |
Why?
|
| Endocrine System | 1 | 2009 | 12 | 0.080 |
Why?
|
| Opiate Alkaloids | 1 | 2009 | 8 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2012 | 307 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2010 | 159 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 143 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2008 | 48 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 83 | 0.070 |
Why?
|
| Stimulation, Chemical | 1 | 2007 | 20 | 0.070 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2019 | 41 | 0.060 |
Why?
|
| Amphetamine | 1 | 2007 | 21 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 27 | 0.060 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2006 | 6 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2006 | 13 | 0.060 |
Why?
|
| Substantia Nigra | 2 | 2004 | 52 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 26 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2018 | 2157 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 66 | 0.060 |
Why?
|
| Social Environment | 1 | 2008 | 218 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 91 | 0.060 |
Why?
|
| Ventral Tegmental Area | 2 | 2002 | 49 | 0.060 |
Why?
|
| Body Weight | 3 | 2013 | 429 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 180 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 986 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 184 | 0.050 |
Why?
|
| Immune System | 1 | 2023 | 41 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 241 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 56 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 549 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 137 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 561 | 0.050 |
Why?
|
| Mice, Obese | 2 | 2018 | 42 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2019 | 389 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 247 | 0.050 |
Why?
|
| Corpus Striatum | 1 | 2004 | 121 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 28 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2003 | 462 | 0.050 |
Why?
|
| Tongue | 1 | 2022 | 16 | 0.050 |
Why?
|
| Sucrose | 1 | 2022 | 33 | 0.050 |
Why?
|
| Taste | 1 | 2022 | 45 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 257 | 0.040 |
Why?
|
| Pyridines | 1 | 2022 | 139 | 0.040 |
Why?
|
| Hypogonadism | 2 | 2012 | 23 | 0.040 |
Why?
|
| Spironolactone | 1 | 2021 | 36 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1271 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 19 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2011 | 117 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2019 | 80 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 138 | 0.040 |
Why?
|
| Hydroxylamines | 1 | 2017 | 4 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 10 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 68 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 75 | 0.030 |
Why?
|
| Fetus | 1 | 2017 | 101 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2017 | 131 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 352 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 10 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 458 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Eosinophils | 1 | 2014 | 24 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 18 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 40 | 0.030 |
Why?
|
| Ion Channels | 1 | 2014 | 74 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 166 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 118 | 0.030 |
Why?
|
| Drug Implants | 1 | 2013 | 20 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 28 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2013 | 34 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 15 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2013 | 41 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2019 | 590 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2544 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 638 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 6081 | 0.020 |
Why?
|
| Energy Intake | 1 | 2011 | 164 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 456 | 0.020 |
Why?
|
| Tetrodotoxin | 1 | 2010 | 22 | 0.020 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2010 | 7 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2010 | 18 | 0.020 |
Why?
|
| Biophysics | 1 | 2010 | 38 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 186 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 228 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2010 | 120 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1410 | 0.020 |
Why?
|
| Carbenoxolone | 1 | 2008 | 10 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2008 | 18 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 75 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 181 | 0.020 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2006 | 2 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2006 | 2 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2006 | 6 | 0.020 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2006 | 25 | 0.020 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 17 | 0.020 |
Why?
|
| Insulin | 1 | 2008 | 258 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 240 | 0.010 |
Why?
|
| Fluorocarbons | 1 | 2006 | 42 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 185 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 701 | 0.010 |
Why?
|
| Mifepristone | 1 | 2005 | 34 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 934 | 0.010 |
Why?
|
| Glucose | 1 | 2005 | 244 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 712 | 0.010 |
Why?
|
| Injections | 1 | 2002 | 42 | 0.010 |
Why?
|
| Neostriatum | 1 | 2002 | 28 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 780 | 0.010 |
Why?
|
| Limbic System | 1 | 2002 | 31 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 592 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2002 | 138 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 275 | 0.010 |
Why?
|